---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-21-000035"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2021-08-11T23:59:59+00:00"
generated_at: "2026-06-29T15:15:40.001838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs reports Q2 net loss of $23.6M; pipeline advances with SL-172154 and SL-279252

## Summary
- Net loss $23.6M ($0.56 loss per share) vs $6.2M ($0.81 loss per share) in Q2 2020; revenue negative $4.2M due to Takeda collaboration cost changes.
- Cash and investments $304.8M as of June 30, 2021; cash runway expected through 2024, beyond Phase 1 results.
- SL-172154 Phase 1 in ovarian cancer: dose escalation at 3.0 mg/kg, plans to advance to 10.0 mg/kg; no dose-limiting toxicities observed.
- SL-279252 Phase 1: additional dose cohorts at 12.0 and 24.0 mg/kg based on pharmacodynamic data; SITC abstracts submitted for November 2021.

## SEC filing metadata
- accession: 0001680367-21-000035
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2021-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036721000035/0001680367-21-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036721000035/sttk-20210811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-21-000035
- JSON: https://secwatch.observer/filing/0001680367-21-000035.json
- Plain text: https://secwatch.observer/filing/0001680367-21-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.